Impact of dose-intense chemotherapy on the development of permanent drug resistance.
Impact of dose-intense chemotherapy on the development of permanent drug resistance.
复制标题
剂量强化化疗对永久性耐药性发展的影响。
DOI：
--
复制
发表时间：
1987
期刊：
影响因子：
--
通讯作者：
Goldie Jh
中科院分区：
文献类型：
--
作者：
Coldman Aj;Goldie Jh
36例费城染色体阳性CML患者接受干扰素α-2b治疗至少3个月。32例患者患有慢性期疾病，4例患有急性期疾病，1例处于爆炸危机。患者最初接受4兆单位/m2的每日剂量皮下给药;门诊患者自我给药，随后根据连续测定的血细胞计数降低剂量。治疗持续0.5至15个月，中位持续时间为7个月。未达到完全缓解，但21例（58%）患者发生血液学缓解，另外12例（33%）患者发生部分血液学缓解。所有四名急性期疾病患者均无反应。不良反应仅在治疗的最初几天内显著，并不干扰药物的自我给药。干扰素α-2b可能被证明是慢性期CML的一种重要的替代治疗方式。
: Thirty-six patients with Philadelphia chromosome-positive CML were treated with interferon alfa-2b for at least 3 months. Thirty-two of the patients had chronic phase disease and four had acute phase disease, one in blast crisis. Patients initially received a daily dose of 4 megaunits/m2 administered subcutaneously; outpatient self administration followed at a dosage decreased in accordance with serially determined blood cell counts. Treatment was continued for 0.5 to 15 months, with a median duration of 7 months. No complete remission was achieved, but hematologic remission occurred in 21 (58%) patients, with partial hematologic remission in an additional 12 (33%). All four patients with acute phase disease failed to respond. Adverse reactions were only significant during the first days of treatment and did not interfere with self administration of the drug. Interferon alfa-2b may prove to be an important alternative therapeutic modality in chronic phase CML.